AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
momelotinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| tyrosine kinase inhibitors | 5745 | 1056634-68-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Momelotinib is an inhibitor of wild type Janus Kinase 1 and 2 (JAK1/JAK2) and mutant JAK2 V617F, which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Momelotinib and its major human circulating metabolite, M21, have higher inhibitory activity for JAK2 compared to JAK3 and tyrosine kinase 2 (TYK2). Momelotinib and M21 additionally inhibit activin A receptor type 1 (ACVR1), also known as activin receptor like kinase 2 (ALK2), which produces subsequent inhibition of liver hepcidin expression and increased iron availability resulting in increased red blood cell production. MF is a myeloproliferative neoplasm associated with constitutive activation and dysregulated JAK signaling that contributes to inflammation and hyperactivation of ACVR1. JAK signaling recruits and activates STAT (signal transducers and activation of transcription) proteins resulting in nuclear localization and subsequent regulation of gene transcription.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.330 | Moderate | 0.67 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 6.166 | Moderate | 0.67 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 46.881 | 10^-6 cm/s | Moderate | 0.67 |
| dh-clint | Dog hepatocyte intrinsic clearance | 5.420 | uL/min/10^6 cells | Moderate | 0.67 |
| dppb | Dog plasma protein binding (% unbound) | 11.460 | % | Moderate | 0.67 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 29.040 | % | Moderate | 0.67 |
| herg | hERG pIC50 | 4.622 | pIC50 | Moderate | 0.67 |
| hh-clint | Human hepatocyte intrinsic clearance | 7.852 | uL/min/10^6 cells | Moderate | 0.67 |
| hlm-clint | Human liver microsomal intrinsic clearance | 14.421 | uL/min/mg protein | Moderate | 0.67 |
| hppb | Human plasma protein binding (% unbound) | 9.020 | % | Moderate | 0.67 |
| kinase-safety-class | AAK1,ABL1,ABL2,ACVR1B,ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK3,CDK4,CDK5,CDK6,CDK7,CDK8,CDK9,CHEK1,CHUK,CLK2,CLK4,CSF1R,CSK,CSNK1G2,DDR1,DYRK1A,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB1,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FLT4,FYN,GAK,GRK1,GRK2,GSK3A,GSK3B,HASPIN,HIPK2,IGF1R,IKBKB,INSR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K4,MAP2K6,MAP2K7,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK15,MAPK3,MAPK7,MAPK8,MAPK9,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,MKNK1,MKNK2,MST1R,MTOR,NTRK1,NTRK2,NTRK3,NUAK1,PAK1,PAK2,PAK4,PAK5,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CD,PIK3CG,PIM2,PIM3,PRKAA1,PRKAA2,PRKACA,PRKCA,PRKCD,PRKCZ,PRKD1,PRKDC,PTK2,RET,RIPK1,RIPK3,ROCK1,ROCK2,RPS6KA1,SGK1,SIK2,SIK3,SRC,STK10,STK16,STK17A,STK3,STK33,STK4,SYK,TBK1,TEK,TGFBR1,TNIK,TNK1,TTK,TYRO3,UHMK1,ULK1,ULK2,YES1,ZAP70 | 172 | |||
| kinase-selectivity-class | AAK1,ACVR2A,ACVR2B,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CHEK1,CHUK,CLK2,CLK4,CSF1R,DDR1,DYRK1A,DYRK1B,DYRK2,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT3,FLT4,FYN,GAK,GRK2,GSK3A,GSK3B,HIPK2,IKBKB,IRAK1,IRAK3,IRAK4,JAK1,JAK2,KDR,KIT,LCK,LRRK2,MAP2K1,MAP2K3,MAP2K6,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,NTRK1,NTRK3,NUAK1,PAK4,PDGFRB,PDK1,PDK4,PIK3CA,PIK3CD,PIK3CG,PRKAA1,PRKAA2,PRKCD,ROCK1,ROCK2,SGK1,SIK2,SIK3,SRC,STK16,STK33,SYK,TEK,TGFBR1,TNIK,TNK1,TTK,TYRO3,ULK1,ULK2,YES1 | 111 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 13.804 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 26.062 | Moderate | 0.67 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 33.497 | Moderate | 0.67 | |
| mppb | Mouse plasma protein binding (% unbound) | 7.980 | Moderate | 0.67 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 25.293 | Moderate | 0.67 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 15.220 | % | Moderate | 0.67 |
| rat-kpuu-brain | Rat brain Kpuu | 0.085 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 19.099 | uL/min/10^6 cells | Moderate | 0.67 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 52.880 | % | Moderate | 0.67 |
| rppb | Rat plasma protein binding (% unbound) | 4.860 | % | Moderate | 0.67 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1.871 | uM | Moderate | 0.67 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 15, 2023 | FDA | GLAXOSMITHKLINE LLC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Thrombocytopenia | 37.70 | 37.05 | 20 | 255 | 190259 | 42430801 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Thrombocytopenia | 53.56 | 40.91 | 25 | 345 | 348860 | 110240069 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EJ04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Janus-associated kinase (JAK) inhibitors |
| MeSH PA | D000075242 | Janus Kinase Inhibitors |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D047428 | Protein Kinase Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:68495 | apoptosis inducer |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:76617 | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Related Drugs by ATC class:
L01EJ Janus-associated kinase (JAK) inhibitors 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Intermediate or high-risk myelofibrosis | indication | 52967002 | DOID:4971 |
| Primary myelofibrosis | indication | 307651005 | |
| Myelofibrosis due to and following polycythemia vera | indication | 871540009 | |
| Myelofibrosis due to and following essential thrombocythemia | indication | 871541008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 100MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 8486941 | Jan. 3, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 150MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 8486941 | Jan. 3, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 200MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 8486941 | Jan. 3, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 100MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 9809559 | June 11, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 100MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | RE48285 | June 11, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 150MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 9809559 | June 11, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 150MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | RE48285 | June 11, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 200MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 9809559 | June 11, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 200MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | RE48285 | June 11, 2035 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| EQ 100MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 12576089 | Aug. 21, 2039 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF AT LEAST 100 BILLION/L BUT LESS THAN 150 BILLION/L AND PREVIOUSLY TREATED WITH A JAK INHIBITOR |
| EQ 150MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 12576089 | Aug. 21, 2039 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF AT LEAST 100 BILLION/L BUT LESS THAN 150 BILLION/L AND PREVIOUSLY TREATED WITH A JAK INHIBITOR |
| EQ 200MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 12576089 | Aug. 21, 2039 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF AT LEAST 100 BILLION/L BUT LESS THAN 150 BILLION/L AND PREVIOUSLY TREATED WITH A JAK INHIBITOR |
| EQ 100MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 11963962 | Dec. 2, 2040 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF LESS THAN 50 BILLION/L |
| EQ 150MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 11963962 | Dec. 2, 2040 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF LESS THAN 50 BILLION/L |
| EQ 200MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | 11963962 | Dec. 2, 2040 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF LESS THAN 50 BILLION/L |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 100MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | Sept. 15, 2028 | NEW CHEMICAL ENTITY |
| EQ 150MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | Sept. 15, 2028 | NEW CHEMICAL ENTITY |
| EQ 200MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | Sept. 15, 2028 | NEW CHEMICAL ENTITY |
| EQ 100MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | Sept. 15, 2030 | TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA |
| EQ 150MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | Sept. 15, 2030 | TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA |
| EQ 200MG BASE | OJJAARA | GLAXOSMITHKLINE | N216873 | Sept. 15, 2023 | RX | TABLET | ORAL | Sept. 15, 2030 | TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase JAK1 | Kinase | INHIBITOR | IC50 | 7.57 | DRUG LABEL | DRUG LABEL | |||
| Tyrosine-protein kinase JAK2 | Kinase | INHIBITOR | IC50 | 8.85 | DRUG LABEL | DRUG LABEL | |||
| Activin receptor type-1 | Kinase | INHIBITOR | IC50 | 8.17 | DRUG LABEL | DRUG LABEL | |||
| Rho-associated protein kinase 1 | Kinase | Kd | 5.87 | CHEMBL | |||||
| Mitogen-activated protein kinase 10 | Kinase | Kd | 5.92 | CHEMBL | |||||
| Rho-associated protein kinase 2 | Kinase | Kd | 6.66 | CHEMBL | |||||
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Kinase | Kd | 6.18 | CHEMBL | |||||
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Kinase | Kd | 6.22 | CHEMBL | |||||
| AP2-associated protein kinase 1 | Kinase | Kd | 8.40 | CHEMBL | |||||
| Serine/threonine-protein kinase MARK2 | Kinase | Kd | 6.21 | CHEMBL | |||||
| Serine/threonine-protein kinase PLK4 | Kinase | Kd | 6.21 | CHEMBL | |||||
| Serine/threonine-protein kinase 16 | Kinase | Kd | 5.89 | CHEMBL | |||||
| BMP-2-inducible protein kinase | Kinase | Kd | 6.38 | CHEMBL | |||||
| Dual specificity protein kinase CLK1 | Kinase | Kd | 6.04 | CHEMBL | |||||
| Cyclin-G-associated kinase | Kinase | Kd | 6.08 | CHEMBL | |||||
| Cyclin-dependent kinase 16 | Kinase | Kd | 5.93 | CHEMBL | |||||
| Mitogen-activated protein kinase 9 | Kinase | Kd | 5.94 | CHEMBL | |||||
| MAP/microtubule affinity-regulating kinase 3 | Kinase | Kd | 6.38 | CHEMBL | |||||
| Cyclin-dependent kinase 9 | Kinase | Kd | 6.13 | CHEMBL | |||||
| Cyclin-dependent kinase 6 | Kinase | Kd | 5.47 | CHEMBL | |||||
| Cyclin-dependent kinase 17 | Kinase | Kd | 5.86 | CHEMBL | |||||
| Casein kinase II subunit alpha' | Kinase | Kd | 6.52 | CHEMBL | |||||
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Kinase | Kd | 6.70 | CHEMBL | |||||
| Serine/threonine-protein kinase SIK2 | Kinase | Kd | 6.10 | CHEMBL | |||||
| Citron Rho-interacting kinase | Kinase | Kd | 6.50 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek9 | Kinase | Kd | 6.32 | CHEMBL | |||||
| Serine/threonine-protein kinase D2 | Kinase | Kd | 6.28 | CHEMBL | |||||
| Serine/threonine-protein kinase D3 | Kinase | Kd | 6.19 | CHEMBL | |||||
| Serine/threonine-protein kinase TBK1 | Kinase | Kd | 6.25 | CHEMBL | |||||
| Serine/threonine-protein kinase ICK | Kinase | Kd | 6.14 | CHEMBL | |||||
| Serine/threonine-protein kinase ULK3 | Kinase | Kd | 6.54 | CHEMBL | |||||
| Serine/threonine-protein kinase SIK3 | Kinase | Kd | 6.07 | CHEMBL | |||||
| Signal transducer and activator of transcription 3 | Transcription factor | IC50 | 5.60 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek3 | Kinase | Kd | 6.54 | CHEMBL | |||||
| Signal transducer and activator of transcription 5A | Transcription factor | IC50 | 6.40 | CHEMBL | |||||
| Uncharacterized protein FLJ45252 | Unclassified | Kd | 8.52 | CHEMBL | |||||
| Uncharacterized aarF domain-containing protein kinase 1 | Kinase | Kd | 6.66 | CHEMBL | |||||
| Cyclin-dependent kinase 2 | Kinase | Kd | 5.67 | CHEMBL | |||||
| Tyrosine-protein kinase JAK3 | Kinase | INHIBITOR | IC50 | 8.21 | SCIENTIFIC LITERATURE | ||||
| Non-receptor tyrosine-protein kinase TYK2 | Kinase | INHIBITOR | IC50 | 7.70 | SCIENTIFIC LITERATURE | ||||
| Dynamin-like 120 kDa protein, mitochondrial | Enzyme | Kd | 6.15 | CHEMBL | |||||
| Histone deacetylase 1 | Enzyme | IC50 | 7.40 | CHEMBL | |||||
| Mitogen-activated protein kinase 8 | Kinase | Kd | 6.22 | CHEMBL | |||||
| Tyrosine-protein kinase JAK2 | Kinase | IC50 | 5.82 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CHEBI:91407 | CHEBI |
| C87 | PDB_CHEM_ID |
| CHEMBL1078178 | ChEMBL_ID |
| C546012 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7791 | IUPHAR_LIGAND_ID |
| DB11763 | DRUGBANK_ID |
| 1366447007 | SNOMEDCT_US |
| 1366449005 | SNOMEDCT_US |
| 4042613 | VANDF |
| C2744845 | UMLSCUI |
| CHEMBL2219411 | ChEMBL_ID |
| CHEMBL6068336 | ChEMBL_ID |
| 9480 | INN_ID |
| 1380317-28-1 | SECONDARY_CAS_RN |
| 25062766 | PUBCHEM_CID |
| 371325 | MMSL |
| 41967 | MMSL |
| d10107 | MMSL |
| 019558 | NDDF |
| 019559 | NDDF |
| 6O01GMS00P | UNII |
| 2665204 | RXNORM |
| D10315 | KEGG_DRUG |
| 6O01GMS00P | INXIGHT DRUGS |
Pharmaceutical products:
None